RARE — Ultragenyx Pharmaceutical Income Statement
0.000.00%
Last trade - 00:00
- $3.64bn
- $3.07bn
- $434.25m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 104 | 271 | 351 | 363 | 434 |
Cost of Revenue | |||||
Gross Profit | 94.7 | 265 | 335 | 335 | 389 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Total Operating Expenses | 528 | 601 | 733 | 1,012 | 1,003 |
Operating Profit | -424 | -330 | -382 | -649 | -569 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -399 | -185 | -453 | -702 | -608 |
Provision for Income Taxes | |||||
Net Income After Taxes | -403 | -187 | -454 | -707 | -607 |
Net Income Before Extraordinary Items | |||||
Net Income | -403 | -187 | -454 | -707 | -607 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -403 | -187 | -454 | -707 | -607 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -7.12 | -3.07 | -6.7 | -10.1 | -8.25 |